ALIXPARTNERS ACQUIRES AGENTIC AI CONSULTING FIRM ARTIUM

KUALA LUMPUR, Aug 5 (Bernama) -- AlixPartners has acquired Artium, an agentic artificial intelligence (AI) software consulting firm that develops enterprise AI agents for clients including BNY Mellon, Mayo Clinic and eBay, as the global consulting firm expands its AI capabilities.

In a statement, the company said Artium will continue operating as a distinct team within AlixPartners under the brand "Artium by AlixPartners", with its people, including its founders, methodology and research relationships remaining unchanged.

AlixPartners Co-Chief Executive Officer (CEO), Rob Hornby said Artium has developed production-grade agentic AI systems and established strong relationships across leading AI research organisations, adding that the combination is expected to enhance the firm's ability to deliver business transformation for clients.

Meanwhile, Artium CEO and Co-Founder, Ross Hale said AlixPartners was selected as the next growth partner because of its understanding of Artium's business, technology capabilities and long-term opportunities, while also supporting the culture and values that have contributed to the firm's growth.

AlixPartners said the acquisition combines Artium's AI engineering capabilities with the firm's industry experience and is expected to create new opportunities to transform businesses and integrate technology across enterprises.

Founded 45 years ago, AlixPartners provides consulting services to companies across a range of industries, focusing on performance improvement, restructuring, transformation and technology-enabled business change.

-- BERNAMA

LENDLEASE REIT REPORTS HIGHER 2H FY2026 REVENUE, DPU

KUALA LUMPUR, Aug 4 (Bernama) -- Lendlease Global Commercial Trust Management Pte Ltd, the manager of Lendlease Global Commercial REIT (Lendlease REIT), has announced its second half (2H) and full-year financial results for FY2026, with gross revenue rising 6.8 per cent year-on-year (YoY) to SG$110.0 million in 2H FY2026. (SG$1 = RM3.19)

In a statement, the company said net property income (NPI) for 2H FY2026 increased 6.6 per cent YoY to SG$78.7 million, driven by the acquisition of PLQ Mall and the performance of its Singapore retail assets, partially offset by the divestment of the Jem office.

Distribution per unit (DPU) for 2H FY2026 stood at 1.85 Singapore cents, bringing the full-year DPU to 3.70 Singapore cents, up 3.0 per cent YoY, supported by recurring earnings from a strong portfolio of operational assets in Singapore.

“FY2026 marked a year of meaningful progress for Lendlease REIT. We took decisive steps to strengthen our financial position through the successful divestment of Jem office, reducing aggregate leverage to 38.9 per cent and improving our interest coverage ratio to 2.1 times.

“Looking ahead, our enlarged Singapore retail portfolio provides a stronger platform for growth. We remain committed to disciplined execution, active asset management and capital stewardship as we pursue further DPU growth and long-term value creation in FY2027,” said the manager’s Chief Executive Officer, Guy Cawthra.

Property operating expenses increased by SG$1.4 million compared with FY2025, mainly due to the acquisition of PLQ Mall, partially offset by the divestment of the Jem office.

As at June 30, 2026, Lendlease REIT’s gross borrowings stood at SG$1.7053 billion, with a gearing ratio of 38.9 per cent. The weighted average cost of debt was reduced to 2.75 per cent per annum, while approximately 68 per cent of borrowings were hedged at fixed rates.

The manager also reduced its outstanding perpetual securities through refinancing exercises undertaken in April 2025 and June 2026, lowering the total quantum from SG$400 million to SG$240 million.

In the same period, Lendlease REIT’s portfolio committed occupancy stood at 94.6 per cent. Its retail portfolio maintained a strong occupancy rate of 98.5 per cent, while occupancy at the Milan office portfolio stood at 89.1 per cent.

The company will continue pursuing active asset initiatives to drive income growth by unlocking value through the reconfiguration of retail space at PLQ Mall and refreshing Discovery Walk to integrate with the multifunctional event space.

-- BERNAMA

2POINTZERO REPORTS STRONG FIRST HALF REVENUE, NET PROFIT

Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire)

KUALA LUMPUR, Aug 4 (Bernama) -- Abu Dhabi-based investment holding firm, 2PointZero Group has reported revenue of 21.9 billion Emirati dirham and a group net profit of 7.7 billion Emirati dirham for the first half of 2026. (100 Emirati dirham = RM111.58)

The group said continued operational integration, wider adoption of artificial intelligence (AI) tools and ongoing cost optimisation strengthened operational performance, lifting revenue while maintaining a blended gross profit margin of 29 per cent.

Net profit from the group's businesses increased 2,301 per cent year-on-year, driven by the consolidation of Tendam and the mega-merger that formed 2PointZero Group, new investments in African financial services, expansion into European packaging markets and steady operational progress across all business segments.

The strong performance was reflected in the group's adjusted earnings before interest, taxes, depreciation and amortisation (EBITDA), which reached 5.0 billion Emirati dirham after excluding fair value changes and one-off items.

“As we enter the second half of the year, we continue to strengthen the platform for long-term growth. Nearly 10 per cent of our workforce consists of AI co-workers, embedded across the group to improve productivity, accelerate decision-making, and strengthen operational performance.

“Together with our disciplined capital allocation and strong financial position, this gives us confidence in our ability to create long-term shareholder value,” said 2PointZero Chief Executive Officer, Samia Bouazza in a statement.

The group's financial position remained strong, supported by cash holdings of 13.7 billion Emirati dirham and a debt-to-equity ratio of 0.32, providing flexibility to manage risks, allocate resources efficiently and fund high-return investment opportunities globally.

Among its key developments, 2PointZero completed the sale of its entire 7.29 per cent stake in TAQA to Abu Dhabi Power and expanded its energy infrastructure portfolio through subsidiary ePointZero's acquisition of a 100 per cent stake in Traverse Midstream Partners.

The group also participated in the Series G funding round for WHOOP, a global health technology company, and acquired a 60.8 per cent controlling interest in Italy's ISEM Packaging Group for 704 million Emirati dirham.

Recognising its financial performance, 2PointZero ranked 36th on TIME's inaugural World's Growth Leaders 2026 list, reflecting its business growth, market performance and long-term financial stability.

-- BERNAMA

Kioxia Unveils CM10 Series SSDs For AI Workloads

 

KIOXIA CM10 Series Enterprise SSD

KUALA LUMPUR, July 30 (Bernama) -- Kioxia Corporation has announced the KIOXIA CM10 Series of solid-state drives (SSDs), featuring its latest BiCS FLASH generation 10 TLC flash memory for enterprise and artificial intelligence (AI) workloads.

According to Kioxia in a statement, the new drives support the NVIDIA CMX architecture while delivering significant improvements in performance, power efficiency and cooling flexibility over the previous generation.

The drives are currently being sampled by selected customers and will be showcased at FMS: The Future of Memory and Storage in Santa Clara from Aug 4 to 6.

The KIOXIA CM10 Series is the company's first PCIe 6.0 enterprise SSD and offers direct cold-plate liquid cooling capability, enabling more efficient cooling for next-generation AI infrastructure.

The series delivers up to approximately 92 per cent higher sequential read performance and up to around 85 per cent higher random read performance, helping to accelerate data-intensive AI inference and enterprise applications while improving overall system efficiency.

As AI models continue to scale toward trillions of parameters and context windows expand to millions of tokens, the demand for high-performance context cache storage is growing rapidly.

Kioxia said the KIOXIA CM10 Series is designed to meet these evolving requirements with the performance, capacity and endurance needed for large-scale AI deployments.

-- BERNAMA

HORIZON QUANTUM TO ENHANCE QUANTUM SYSTEMS EFFICIENCY WITH QM

Horizon Quantum's CEO Dr. Joe Fitzsimons and Quantum Machines' CEO Dr. Itamar Sivan at Horizon Quantum's quantum hardware testbed

 
KUALA LUMPUR, July 30 (Bernama) -- Horizon Quantum Computing Pte Ltd (Horizon Quantum), a pioneer in software infrastructure for quantum applications, has entered into a strategic collaboration with Q.M Technologies Ltd (QM) to develop more robust and efficient quantum systems.

According to Horizon Quantum in a statement, the collaboration will leverage QM's quantum control platform and engineering expertise to develop embedded calibration technologies for its first in-house hardware testbed system, Ember-1, with the aim of delivering more reliable, continuously operating quantum systems.

Horizon Quantum Chief Executive Officer, Dr Joe Fitzsimons said this strategic collaboration provides an opportunity to contribute to the development of more stable and high-performing quantum systems.

“By bringing together Horizon Quantum’s expertise in quantum software and QM’s expertise in quantum control, I believe we can develop lightweight calibration routines that increase uptime and improve the reliability of our testbed system,” he said.

The company said it intends to develop an embedded calibration framework that enables lightweight calibration routines to be executed during normal system operation, reducing reliance on lengthy full-system calibration cycles.

By updating system parameters more frequently, the framework is designed to reduce downtime, improve operational stability and maintain high-performance operation over extended runtimes.

Horizon Quantum will also leverage QM's OPX1000 control system to support the development, with improved Ember-1 uptime expected to increase access time for Triple Alpha users.

The collaboration reflects both companies' commitment to advancing practical quantum computing by combining quantum software and control technologies to support scalable, high-performance quantum systems.

-- BERNAMA

CryptoRank Study Finds Bitget rTokens Recorded Up to 58% Lower Slippage on $50,000 Orders Across Leading Tokenized Equity Platforms

VICTORIA, Seychelles, July 28 (Bernama-GLOBE NEWSWIRE) -- Bitget, the world's largest Universal Exchange (UEX), ranked first for large-order execution in a CryptoRank study evaluating liquidity, market structure and execution quality across leading tokenized equity products. The research found that Bitget's Reality rTokens delivered the lowest simulated slippage across every comparable asset tested, recording up to 58% lower slippage on $50,000 orders than competing tokenized equity products, highlighting the growing importance of execution quality as tokenized equities continue to mature.

The report arrives as the tokenized equity market approaches $2 billion in onchain value with more than 471,000 onchain holders, reflecting growing investor demand for blockchain-based access to traditional financial assets. As tokenized stocks become more widely available across crypto exchanges, CryptoRank examined how differences in product structure, liquidity models and execution infrastructure influence the trading experience beyond simple price exposure.

The study compared tokenized stock offerings across major exchanges and found that products tracking the same underlying equities can differ significantly in investor rights, liquidity mechanisms, redemption models and execution quality. The report evaluated NVIDIA, Microsoft, Meta and Tesla, the only four assets that maintained valid two-sided order books across all venues tested. In this comparable set, Bitget's Reality rTokens consistently produced the strongest execution results for larger trades.

The report found that Bitget delivered the lowest simulated slippage across all four comparable assets for both $10,000 and $50,000 orders, while Reality rTokens recorded the highest balanced displayed liquidity within 50 basis points. CryptoRank attributed these results to Bitget's liquidity architecture, which combines exchange liquidity with NYSE and NASDAQ-linked underlying market liquidity, enabling deeper liquidity and more efficient execution for larger trades. CryptoRank also examined the legal and operational structures behind tokenized equity products, noting that similar stock tickers can represent different forms of investor claims depending on how each product is issued and settled.

“Tokenization is moving beyond access and into infrastructure," said Gracy Chen, CEO at Bitget. “If even 10% of global financial assets become tokenized by 2030, we’ll witness one of the most significant transformations in modern capital markets. The next phase of tokenization will be defined by quality of execution liquidity and market infrastructure supporting those assets. Independent research like this helps establish the benchmarks the industry needs as tokenzied markets continue to mature.”

The findings build on Bitget's continued expansion of its Stock+ ecosystem, which gives eligible users access to more than 500 tokenized stocks, ETFs, commodities and other traditional financial assets alongside cryptocurrencies through a single unified account. By combining 24/7 market access, fractional investing and NYSE and NASDAQ-linked liquidity, Bitget is building the infrastructure needed to support the next generation of tokenized capital markets.

Read the CryptoRank report here.

About Bitget

Bitget is the world's largest Universal Exchange (UEX), serving over 125 million users and offering access to over 2M crypto tokens, 500+ tokenized stocks, ETFs, commodities, FX, and precious metals such as gold. The ecosystem is committed to helping users trade smarter with its AI agent, which co-pilots trade execution. Bitget is driving crypto adoption through strategic partnerships such as MotoGP™. Aligned with its global impact strategy, Bitget has joined hands with UNICEF to support blockchain education for 1.1 million people by 2027. Bitget currently leads in the tokenized TradFi market, providing the industry's lowest fees and highest liquidity across 150 regions worldwide.

For more information, visit: Website | X | Telegram | LinkedIn | Discord

For media inquiries, please contact: media@bitget.com

Risk Warning: Digital asset prices are subject to fluctuation and may experience significant volatility. Investors are advised to only allocate funds they can afford to lose. The value of any investment may be impacted, and there is a possibility that financial objectives may not be met, nor the principal investment recovered. Independent financial advice should always be sought, and personal financial experience and standing carefully considered. Past performance is not a reliable indicator of future results. Bitget accepts no liability for any potential losses incurred. Nothing contained herein should be construed as financial advice. For further information, please refer to our Terms of Use.

Photos accompanying this announcement are available at

https://www.globenewswire.com/NewsRoom/AttachmentNg/3c8f2a89-2b0b-465f-9fe6-d03b919d5754

https://www.globenewswire.com/NewsRoom/AttachmentNg/2fd67267-7705-42b5-82f2-dc4dbe7c590b 

SOURCE: Bitget Limited

DISCLAIMER: BERNAMA MREM are not accountable for any causes of website defacement, misuse, or illegal activities connected to cryptocurrency, blockchain, tokenisation, or bitcoin. This material should not be considered as guidance or an opinion, as it does not constitute financial or investment advice. Use this information at your own risk; we are not liable for any losses or damages caused by the republication of this article.

--BERNAMA

AGC Biologics Lands Commercial Manufacturing Agreement for Yokohama Site Worth Hundreds of Millions of Dollars

 

• Commercial long-term deal with a large pharmaceutical company pursuing manufacturing and commercial regulatory approvals in major markets
• Customer commits to AGC Biologics’ new site in Yokohama for five commercial biologics programs
• Highlights growing demand for geopolitically stable supply chains, positioning Japan as an allied hub for global supply of biopharmaceuticals

YOKOHAMA, Japan, July 29 (Bernama-GLOBE NEWSWIRE) -- Ahead of the official opening of AGC Biologics’ Yokohama site, an international biopharmaceutical company has already secured half of the facility’s mammalian manufacturing capacity with a multi-year commercial contract expected to reach hundreds of millions of dollars in total value. The Contract Development and Manufacturing Organization (CDMO) will leverage its new Yokohama facility to manufacture a minimum of 35 batches per year of five biopharmaceutical products for the undisclosed customer, securing a reliable global supply chain for patients worldwide.

The agreement includes process transfer, scale-up, regulatory validation, and future commercial production. The customer will pursue multiple regulatory approvals with the EMA, FDA, MHRA, and PMDA. The aggressive manufacturing timeline includes four process performance qualifications (PPQ) campaigns in the first two years. 

Securing commercial production in Japan reflects a broader industry shift toward supply chain resilience, as global biopharmaceutical developers increasingly prioritize established, geopolitically stable manufacturing partners with locations that mitigate geopolitical, regulatory and trade risks.

“AGC Biologics has the largest global network of single-use manufacturing capacity by volume outside of China, but that’s not the full story,” said Alberto Santagostino, President and CEO of AGC Biologics. “The market is demanding capable, reliable manufacturing partners with global quality standards and geographic flexibility. This agreement reflects the strength of our network, our single-use expertise, and the strategic role Japan can play in resilient biologics supply chains. Our newest Japan site in Yokohama synthesizes all our network learning in a location of increasing interest, and that carries the intrinsic cultural value of manufacturing quality and effective delivery.”

Once operational in 2027, the Yokohama site will deploy four 2,000-liter Cytiva single-use bioreactors and two 5,000-liter Thermo Fisher Scientific DynaDrive single-use bioreactors, adding 18,000 liters to AGC Biologics’ existing capacity of single-use technology for biologics manufacturing. Select customers and guests are scheduled to be provided with the opportunity to visit the new site in December 2026, when construction is completed.

“Securing a major commercial partner for Yokohama before the site is operational is a strong signal of confidence in what this facility will offer,” said Tadashi Murano, President of AGC Life Science Company. “With the site located adjacent to the AGC Yokohama Technical Center, biopharmaceutical developers are understanding that choosing a CDMO with an established innovation ecosystem in Japan is a smart outsourcing strategy.”

The AGC Biologics’ Yokohama site was part of the biomanufacturing investments made by Japan’s Ministry of Economy, Trade and Industry in 2022. These strategic investments are designed to expand domestic production and reinforce Japan’s position as a highly trusted, long-term biologics partner for life sciences industries within allied nations.

Services available in Yokohama starting in 2027 will include:

• Mammalian development and GMP manufacturing, with two downstream lines and flexible single-use bag capacity of 18,000 liters.
• Cell therapy services with six clean rooms.
• Messenger RNA (mRNA) development and manufacturing with 2 IVT, two purification lines, and two LNP lines. 

With existing cGMP manufacturing locations in the U.S., Japan, and Europe, AGC Biologics’ track record will help kick off the manufacturing operation in Yokohama, utilizing the experience of:

• More than three decades of GMP experience.
• 100 successful regulatory inspections.
• More than 30 commercial products launched, which received more than 100 separate regulatory agency approvals.
• More than 400 products developed and manufactured for over 250 different customers.

About AGC Biologics

AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. AGC Biologics is a part of AGC Inc.’s Life Science Business. The Life Science Business runs eight facilities focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. To learn more, visit www.agcbio.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4834252b-9e14-45c2-987f-d437e07479e4

AGC Inc. corporate contact: info-pr@agc.com

AGC Biologics media contact: kati.sills@agc.com

SOURCE: AGC Biologics, Inc.